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licenses/by/4.0/).Abstract Background: Oesophageal (OeC) and gastric (GC) cancer patients are treated with
similar multimodal therapy and have poor survival. There remains an urgent clinical need to
identify biomarkers to individualise patient management and improve outcomes. Therapy
with immune checkpoint inhibitors has shown promising results in other cancers. Proposed
biomarkers to predict potential response to immune checkpoint inhibitors include DNA
mismatch repair (MMR) and/or EpsteineBarr virus (EBV) status. The aim of this study
was to establish and compare EBV status and MMR status in large multi-centre series of
OeC and GC.
Methods: EBV was assessed by EBV-encoded RNA (EBER) in situ hybridisation and
MMR protein expression by immunohistochemistry (IHC) in 988 OeC and 1213 GC fromof Pathology, Maastricht University Medical Center, P. Debyelaan 25, Maastricht, 6229 HX, The
htuniversity.nl (H.I. Grabsch).
4
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L.C. Hewitt et al. / European Journal of Cancer 94 (2018) 104e114 105multiple centres. In a subset of OeC, microsatellite instability (MSI) was tested in parallel
with MMR IHC.
Results: Frequency of MMR deficiency (MMRdef) and MSI was low in OeC (0.8% and
0.6%, respectively) compared with GC (10.3%). None of the OeCs were EBER positive
in contrast to 4.8% EBER positive GC. EBV positive GC patients were younger
(p Z 0.01), more often male (p Z 0.001) and had a better overall survival (p Z 0.012).
MMRdef GC patients were older (p Z 0.001) and showed more often intestinal-type his-
tology (p Z 0.022).
Conclusions: This is the largest study to date indicating that EBV and MMRdef do not play
a role in OeC carcinogenesis in contrast to GC. The potential clinical usefulness of deter-
mining MMRdef/EBV status to screen patients for eligibility for immune-targeting therapy
differs between OeC and GC patients.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Oesophageal cancer (OeC) and gastric cancer (GC) are
the eighth and fifth most common cancer worldwide,
respectively, with an estimated total of 1,407,000 new
cases and 1,123,000 deaths in 2012 [1]. The two main
histological OeC subtypes are squamous cell carcinoma
(SqC) and adenocarcinoma (AdC). The vast majority of
GCs are adenocarcinomas.
In Europe, the standard of care for OeC and GC
patients with locally advanced resectable disease is
chemotherapy or chemoradiotherapy, followed by sur-
gery [2,3]. GC patients receive perioperative platinum/
fluorouracil based chemotherapy. For OeC, patients
with SqC are treated with preoperative chemo-
radiotherapy with carboplatin/paclitaxel. Patients with
AdC receive perioperative platinum/fluorouracil or
preoperative chemoradiotherapy. Nevertheless, survival
remains poor, with 5-year overall survival between 36
and 47% [4,5].
To date, few targeted therapy options are available to
OeC/GC patients with metastatic disease: trastuzumab
for HER2 positive disease [6] and ramucirumab, a
VEGFR-2 antagonist without biomarker based patient
selection [7,8]. All other trials evaluating receptor tyro-
sine kinase or downstream signalling inhibitors in OeC/
GC were unable to show a survival benefit [9]. There re-
mains an urgent clinical need to identify biomarkers to
individualise and improve OeC/GC patient management.
DNA mismatch repair (MMR) has been used as a
predictive biomarker for PD1 inhibitor therapy response
in multiple different cancer types, including colorectal
cancer [10]. Evidence of Epstein-Barr virus (EBV)
infection has been proposed as a potential marker for
response to PD1/PDL1 inhibitors in GC [11]. Pem-
brolizumab, an antibody against PD1, was approved by
the FDA for the treatment of unresectable or metastatic
solid tumours, including OeC and GC, with mismatch
repair deficiency (MMRdef) or microsatellite instability
(MSI)-High [12].The potential of immunotherapy in OeC was shown
recently in phase 2 trials in non-selected oesophageal
SqC and GC patients treated with nivolumab, a mon-
ocolonal antibody inhibiting PD1, in second line treat-
ment [13,14] and in a phase 3 trial in heavily pretreated
non-selected Asian GC patients [15]. Furthermore,
recent results from the phase 1b trials in patients with
PD-L1 expressing OeC (KEYNOTE-028) and GC
(KEYNOTE-012), showed promising activity of pem-
brolizumab in the metastatic setting [16,17]. In meta-
static colorectal cancer, a phase 2 study demonstrated
the clinical benefit of pembrolizumab in patients with
MMRdef [18].
In addition to the potential role of MMR proteins in
selecting patients for immunotherapy, MMRdef has
shown prognostic value [19] and seems to predict a poor
response to fluorouracil based chemotherapy in colo-
rectal cancer [20,21]. It has been shown recently in
MAGIC trial patients, that gastro-oesophageal cancer
patients with MMRdef/MSI tumours treated with sur-
gery alone survived longer compared with those treated
with perioperative cytotoxic chemotherapy [22]. In OeC,
MLH1 and MSH2 deficiency has been shown to be
associated with poor prognosis in small series of SqC [23].
To date, the frequency of MMRdef/MSI in OeC
cancer remains unclear because of the small sample size
of studies. The reported frequency of MSI-High (MSI-
H) ranges from 0 to 27%, but a number of previous
studies did not distinguish between MSI-H and MSI-
Low (MSI-L) (for an overview of all published studies
on MMR and MSI in OeC, see Table 1). The recent
study by The Cancer Genome Atlas (TCGA) did not
find MSI in any of the 162 OeC [24]. With respect to the
frequency of EBV infection in OeC, the majority of
previous studies investigated SqC using different meth-
odology, included relatively small number of patients
and reported a frequency of EBV positivity from 0 to
36% (for an overview of all published studies on EBV in
OeC, see Table 2). Thus, neither MSI/MMRdef nor
EBV status has been investigated in large series of OeC
Table 1
Summary of published literature relating to the frequency of mismatch repair deficiency and microsatellite instability in oesophageal cancer.
Authors Year Oesophageal cancer type Total n MMRdef n (%) MSI-High n (%) Method
TCGA [24] 2017 SqC 90 NI 0 PCR
AdC 70 0
undiff 2 0
Pandilla et al. [57] 2013 SqC 60 NI 6 (10) PCR
AdC 30 2 (7)
Farris et al. [38] 2011 SqC 76 5 (7) 5 (7) IHC, PCR
Vasavi et al. [44] 2010 SqC 45 NI 12 (27) PCR
AdC 5 1 (20)
Matsumoto et al. [58] 2007 SqC 62 NI 5 (8) PCR
Falkenback et al. [48] 2005 AdC 59 2 (3) 2 (3) IHC, PCR
Naidoo et al. [59] 2005 SqC 100 NI 5 (5)a PCR
Uehara et al. [23] 2005 SqC 122 49 (40) 6 (5)a IHC
Evans et al. [47] 2004 AdC 27 6 (22) 0 IHC, PCR
Araki et al. [45] 2004 SqC 100 NI 0 PCR
Hayashi et al. [60] 2003 SqC 30 NI 1 (3) PCR
Ikeguchi et al. [46] 1999 SqC 20 NI 1 (5)a PCR
Wu et al. [61] 1998 SqC 92 NI 5 (5)a PCR
Muzeau et al. [43] 1997 SqC 20 NI 0 PCR
AdC 26 0
Gleeson et al. [62] 1996 AdC 17 NI 1 (17) PCR
Keller et al. [63] 1995 AdC 15 NI 2 (13)a PCR
Ogasawara et al. [64] 1995 SqC 35 NI 21 (60)a PCR
Meltzer et al. [65] 1994 SqC 42 NI 1 (2)a PCR
AdC 36 2 (6)a
Abbreviations: AdC, adenocarcinoma; SqC, squamous cell carcinoma; MMRdef, mismatch repair deficiency; MSI, microsatellite instability; PCR,
polymerase chain reaction; IHC, immunohistochemistry; NI, not investigated; undiff, undifferentiated.
a no distinction made between MSI-High and MSI-Low.
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clinicopathological variables and patient survival.
The aim of this multi-centre study was to establish
the EBV and MMR/MSI status in 988 OeC, includingTable 2
Summary of published literature relating to the frequency of Epstein-
Barr virus in oesophageal cancer.
Reference Year Oesophageal
cancer type
Total
n
EBV
positive
n (%)
Method
TCGA [24] 2017 SqC 90 0 Whole-exome
sequencingAdC 70 0
undiff 2 0
Genitsch et al. [34] 2015 AdC 118 0 EBER ISH
Farris et al. [38] 2011 AdC 76 1 (1) EBER ISH
Sunpaweravong
et al. [36]
2005 SqC 104 0 EBER ISH
Wu et al. [39] 2005 SqC 151 6 (4) EBER ISH
undiff 13 4 (31)
Awerkiew
et al. [40]
2003 SqC 23 8 (35) PCR
AdC 14 5 (36)
Yanai et al. [33] 2003 SqC 34 0 EBER ISH,
PCR
Mizobuchi
et al. [37]
1997 SqC 41 0 PCR
Wang et al. [35] 1999 SqC 51 0 EBER ISH,
PCR
Wang et al. [41] 1999 SqC 31 11 (36) EBER ISH,
PCR
Abbreviations: AdC, adenocarcinoma; SqC, squamous cell carcinoma;
EBER ISH, EBV-encoded RNA in situ hybridisation; PCR, poly-
merase chain reaction; undiff, undifferentiated.patients from the Medical Research Council (MRC)
Oe02 trial [25], from Leeds (UK) and from Cologne
(Germany) and relate the results to clinicopathological
variables, survival and treatment interaction (preopera-
tive chemo(radio)therapy). As patients with resectable
OeC and GC are often treated using similar neoadjuvant
therapy regimens and recruited into the same clinical
trials across different countries or continents, we
compared the frequency of EBV positivity and
MMRdef in OeC with that of 1213 GC from Leeds
(UK) and Yokohama (Japan).2. Material and methods
2.1. General remarks
The definition whether a tumour is a gastric or oeso-
phageal cancer is dependent on the macroscopic loca-
tion of the bulk/epicentre of the tumour with respect to
the gastro-oesophageal junction. Macroscopic images
were not available to us for review as part of this study
with the exception of the Japanese gastric cancer cases.
In contrast to our Japanese colleagues who classify
tumours as oesophageal, junctional or gastric, all other
pathologists using the TNM classification categorise
tumours as being either oesophageal or gastric. We
therefore reviewed the macroscopic images from the
Japanese junctional cancers to classify them as either
oesophageal or gastric according to TNM rules. For all
L.C. Hewitt et al. / European Journal of Cancer 94 (2018) 104e114 107other cases, we have used the classification of the
originally reporting pathologist.
2.2. Oesophageal cancer cohorts
2.2.1. UK MRC Oe02 trial
The Oe02 trial was a multi-centre phase 3 trial
comparing preoperative chemotherapy (cisplatin þ 5-
fluorouracil) followed by surgery (CS group) to surgery
alone (S group) in 802 OeC patients with locally
advanced resectable disease, recruited from March 1992
to June 1998. Paraffin blocks of the resected primary
tumour were collected retrospectively, and material
from 443 patients was available for the present study
(CS n Z 212, S n Z 231). Clinicopathological data
which could not be established during the central pa-
thology review were retrieved from pathology reports
and the clinical trial database. The study was approved
by the South East Research Ethics committee, London,
UK, REC reference: 07/H1102/111.
2.2.2. Leeds Teaching Hospitals NHS Trust (LTHT),
UK
The LTHT cohort included 223 OeC patients who
underwent potentially curative surgery at the Depart-
ment of Surgery, Leeds General Infirmary (Leeds,
UK), between 1986 and 2006. A total of 83 patients
had preoperative chemotherapy. Clinical and patho-
logical data were retrieved from pathology reports,
electronic patient hospital records and the Northern
and Yorkshire Cancer Registry. The study was
approved by the Leeds Research Ethics Committee
(LREC No. CA01/122).
2.2.3. University Hospital Cologne (UHC), Germany
The UHC cohort included 322 OeC patients who un-
derwent potentially curative surgery at the Department
of Visceral Surgery, University of Cologne (Cologne,
Germany), between 1999 and 2013. A total of 197 pa-
tients had preoperative chemotherapy. Clinical and
pathological data were retrieved from pathology reports
and electronic patient hospital records. The study was
approved by the Ethics Committee at the University
Hospital, Cologne (reference number: 09-232).
2.3. Gastric cancer cohorts
2.3.1. Leeds Teaching Hospitals NHS Trust, UK
The GC LTHT cohort included 799 patients who un-
derwent potentially curative surgery at the Department
of Surgery, Leeds General Infirmary (Leeds, UK) be-
tween 1970 and 2004. Eleven patients had preoperative
chemotherapy. Demographical, clinical and patholog-
ical data were retrieved from pathological reports,
electronic patient hospital records and the Northern and
Yorkshire Cancer Registry. The study was approved bythe Leeds Research Ethics Committee (LREC No.
CA01/122).
2.3.2. Kanagawa Cancer Center Hospital (KCCH),
Yokohama, Japan
The KCCH cohort included 414 patients with stage II-
IV GC who underwent potentially curative surgery at
the Kanagawa Cancer Center Hospital (Yokohama,
Japan) between 2001 and 2010. None of the patients
had preoperative chemotherapy, 202 patients were
treated with chemotherapy after surgery. Demograph-
ical, clinical and pathological data were retrieved from
pathological reports and patient hospital records. The
study was approved by the Local Research Ethics
Committee.
2.4. Methods
2.4.1. Cancer staging and histological subtyping
pT and pN stage was reported according to the Union
for International Cancer control 6th and 7th edition of
the TNM classification for OeC and GC, respectively.
The histological subtype of adenocarcinomas was
established based on Lauren’s classification [26]. Ac-
cording to Lauren’s classification, signet-ring cell GCs
were classified as diffuse-type cancer. As there is no
category for mucinous cancers in the Lauren classifica-
tion, such cancers were classified together with the
mixed-type cancers which we used as a category for truly
mixed-type cancers and cancers with indeterminate
phenotype like the mucinous cancers. The histology type
of the case, as stated in the pathology report, was used
for statistical analyses.
2.4.2. Tissue microarray construction
Slides from all resection specimens were reviewed and
a block with the highest tumour cell density was
selected for tissue microarray (TMA) construction
and/or marked for microdissection for DNA extrac-
tion (see below). The areas selected were representative
of the overall histology of the case. The LTHT,
KCCH, and Oe02 trial cases were reviewed by HG,
LH and GH, together with local pathologists. The
UHC cases were reviewed by AQ. A total of 962 OeCs
(417, 223 and 322 patients from the Oe02, LTHT and
UHC cohorts, respectively) and 1213 GCs (799 and
414 patients from LTHT and KCCH cohorts, respec-
tively) were included in TMAs. TMA construction
from the LTHT (OeC and GC) and Oe02 patient co-
horts was performed using 0.6 mm tissue cores;
1.2 mm and 1 mm tissue cores were used for the UHC
and KCCH cohorts, respectively.
2.4.3. Immunohistochemistry for mismatch repair proteins
MMR immunohistochemistry (IHC) data from previous
studies were available for 230 KCCH [27] and 175
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GCs were stained as part of the present study.
TMA sections from the Oe02 trial cohort were
stained for MLH1, MSH2, MSH6, PMS2, from the
UHC cohort for MLH1, MSH2 and MSH6 and from
the KCCH and LTHT cohort (OeC and GC) for MLH1
and MSH2. For details on antigen retrieval, primary
antibodies, detection system, staining protocols see
Table 1 in the supplementary material. For all cohorts,
3,30-Diaminobenzidine (DAB) was used as a chromogen
and haematoxylin as a counterstain.
A case was classified as MMR deficient (MMRdef) if
tumour cell nuclei were negative for one or more MMR
proteins in the presence of positively stained lympho-
cytes or fibroblasts as internal control. In the Oe02 trial
cohort, 12 cases were negative for at least one MMR
protein without positive internal controls on the TMA.
For these cases, IHC was repeated on full sections. A
case was classified as MMR proficient (MMRprof) if
tumour cell nuclei, irrespective of the number or in-
tensity, were positive for all MMR proteins tested.
2.4.4. EBV RNA in situ hybridisation
EBV data from a previous study were available for 437
LTHT and 216 KCCH GC [28]. Additional 362 LTHT
and 198 KCCH GCs were stained as part of the present
study. EBV status was determined on TMAs in the
LTHT (OeC and GC), Oe02 and KCCH cohorts by
EBV-encoded RNA (EBER) in situ hybridisation as
previously described [29]. In the UHC cohort, a
fluorescein-conjugated oligonucleotide probe in
conjunction with a monoclonal anti-fluorescein anti-
body and DAB as chromogen (Leica Biosystems, Wet-
zlar, Germany) was used according to the instructions of
the manufacturer. EBV positivity was defined as pres-
ence of staining in tumour cell nuclei, irrespective of the
number of nuclei or intensity.
2.4.5. DNA extraction
DNA was extracted using a protocol based on the
QIAmp DNA Micro Kit (Qiagen, Hilden, Germany) as
previously described [30]. DNA concentration was
measured by ND-100 Spectrophotometer (Labtech In-
ternational) and adjusted to a final concentration of
1 ng/ml.
2.4.6. Assessment of microsatellite instability
The MSI Analysis System, version 1.2 (Promega,
Southampton, UK), was used for the detection of MSI
in 419 Oe02 patients. This kit allows the simultaneous
evaluation of 5 fluorescently labelled MSI markers:
BAT-25, BAT-26, NR-21, NR-24 and MONO-27. PCR
products were analysed using a 3100-Avant genetic
analyser (Applied Biosystems, California, USA) as
previously described [27]. Instability in two or more
microsatellite loci was categorised as MSI-high (MSI-H)
and in a single loci as MSI-low (MSI-L). Absence ofMSI in all 5 markers and MSI-L were grouped as mi-
crosatellite stable (MSS) for further analyses following
current guidelines [31].
2.4.7. Statistical analyses
All statistical analyses were performed using SPSS
version 23 software (SPSS Inc., Chicago, III). The rela-
tionship between EBV or MMR status and clinicopath-
ological variables (age, gender, depth of invasion (pT),
lymph node status (pN), Lauren classification and neo-
adjuvant treatment) were assessed using chi-squared for
categorical variables and Mann-Whitney U for contin-
uous variables. LTHT and KCCH GC data were com-
bined for the analysis of the relationship between EBV or
MMR status and overall 5-year survival and differences
were assessed using the log rank test. P values less than
0.05 were considered significant.
3. Results
3.1. EBV status
EBV data were available from 928 OeC patients (LTHT
n Z 223; Oe02 n Z 383; UHC n Z 322) and 1178 GC
patients (LTHT n Z 768; KCCH n Z 410). All OeC
were EBV negative. A total of 56 (4.8%) GC were EBV
positive (LTHT: nZ 30 [3.9%], KCCH: nZ 26 [6.3%]).
Supplementary figure 1 illustrates EBV staining in GC.
3.2. Microsatellite status and mismatch repair protein
expression
MSI data were available from 362 OeC from the Oe02
cohort. A total of 57 (13.6%) cases had to be excluded
due to repeated technical failures. A total of 356 (98.3%)
OeC patients were classified as MSS, 4 (1.1%) OeC as
MSI-L (3 AdC and 1 SqC) and 2 (0.6%) OeC as MSI-H
(both AdC). Supplementary figure 2 shows a typical
capillary electrophoresis output for a MSI-H OeC and a
MSS OeC. For 306 patients, MMR IHC (MLH1,
MSH2, MSH6 and PMS2) data and MSI testing results
were available and showed 99.0% concordant results.
We therefore decided to only use IHC for the remaining
cohorts.
MMR expression data were available from a total of
916 OeC (LTHT n Z 220; Oe02 n Z 374; UHC
n Z 322). A sum of 43 (10.3%) and 3 (1.3%) OeC from
the Oe02 and LTHT cohorts, respectively, were
excluded due to technical failures. Seven (0.8%) OeC (5
AdC and 2 SqC) were classified as MMRdef (LTHT: 3
(1.4%) MLH1 deficient, Oe02: 1 (0.3%) MSH2 deficient,
UHC: 3 (0.9%) MLH1 deficient). Patient clinicopatho-
logical variables and MMR status for OeC are sum-
marised in Table 3. Owing to the very small number of
MMRdef in OeC, it was not feasible to perform any
statistical analysis with clinicopathological data or
survival.
Table 3
Mismatch repair status and clinicopathological variables in patients with oesophageal cancer.
Clinicopathological variables Mismatch repair proficient Mismatch repair deficient
LTHT Oe02 UHC LTHT Oe02 UHC
n % n % n % n % n % n %
Sex Male 137 63.1 294 78.8 287 89.9 2 66.7 3 100
Female 80 36.9 79 21.2 32 10.1 1 33.3 1 100
(y)pT(6) T0 2 0.9 3 0.9
T1 32 14.7 27 7.2 63 19.7 1 33.3
T2 38 17.5 36 9.7 63 19.7 1 33.3
T3 136 62.7 301 80.7 185 58 2 66.7 1 100 2 66.7
T4 9 4.1 9 2.4 5 1.6
(y)pN(6) N0 83 38.2 123 33 122 38.2 1 100 3 100
N1 133 61.3 250 67 197 61.8 3 100
unknown 1 0.5
Histological type Adenocarcinoma 165 76 275 73.7 319 100 2 66.7 3 100
Squamous cell carcinoma 49 22.6 87 23.3 1 33.3 1 100
Other 3 1.4 11 2.9
Neoadjuvant treatment Yes 80 36.9 177 47.5 194 60.8 2 66.7 1 100 2 66.7
No 133 61.3 196 52.5 125 39.2 1 33.3 1 33.3
unknown 4 1.8
Abbreviations: LTHT, Leeds Teaching Hospital Trust; Oe02, oesophageal cancer trial 02 [25]; UHC, University Hospital Cologne.
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1098 GC (LTHT n Z 702; KCCH nZ 396). A total of
113 (10.3%) cases were classified as MMRdef (LTHT: 70
(10.0%), KCCH: 43 (10.9%)). Supplementary figure 3
illustrates MMR protein expression in a MMRdef GC.
For 1063 GCs, both EBV and MMR data were
available. A single GC from the LTHT cohort was
MMRdef and EBV positive. This patient was male, 67
years old at the time of diagnosis and survived 17 years
despite having an advanced intestinal-type GC (pT4,
pN3) in the resected specimen.
3.3. Relationship of EBV status and MMR status with
clinicopathological variables in patients with gastric
cancer
Patients with EBV positive GC were younger (median
[range] age EBV positive GC: 63 years (32e89 years)
versus 68 years (14e96 years) in EBV negative GC,
p Z 0.01). A total of 48 (85.7%) patients with EBV
positive GC were male compared with 8 (14.3%) of
female patients (p Z 0.001). EBV positive GC patients
had a better overall 5-year survival compared with
EBV negative GC patients (60.7% versus 41.7%; hazard
ratio 1.72, 95% confidence interval 1.12e2.63
[p Z 0.012]).
Patients with MMRdef GC were older (median
[range] age MMRdef GC: 71 years [51e90 years] versus
68 years [24e96 years] in MMRprof GC, pZ 0.001). A
total of 77 (69.4%) MMRdef GC had intestinal-type
histology compared with 20 (18.0%) with diffuse-type
histology (pZ 0.022). There was no difference in overall
survival between MMRdef and MMRprof GCs
(p Z 0.383). There was no relationship with any other
clinicopathological variables (Table 4).A summary of the EBV, MMR and MSI status in
each cohort is provided in Table 5.
4. Discussion
This is the largest gastro-oesophageal cancer study to
date investigating MMR and EBV status in 988 OeC
and 1213 GC. The extremely low frequency of MMR/
MSI and lack of EBV infection in OeC relative to GC in
our study confirms the recent TCGA results which
investigated MSI and EBV in smaller series of 164 OeC
[24] and 295 GC [11] using different methodologies.
All OeC were EBV negative which is consistent with
the majority of previously published studies [32e37].
Therefore, we can conclude now that EBV does not play
a role in OeC carcinogenesis neither in SqC nor in AdC.
A small number of previous studies reported an EBV
positivity rate between 1 and 36% in OeC [38e41]. This
discrepancy is most likely related to different potentially
less reliable methodology, such as PCR, which would
also detect EBV in tumour-infiltrating lymphocytes [33]
leading to false positive results. The present study used
the generally accepted ‘gold standard’ EBER method-
ology. In our study, EBV positive GC patients had a
significantly better overall survival compared with EBV
negative patients which is consistent with results from
other studies [42].
In the Oe02 cohort, we detected a very low frequency
of MSI-H (0.6%) using the Bethesda microsatellite
panel [31]. This result is consistent with the recent
smaller TCGA study which found no MSI-H cases in
72 oesophageal AdC [24]. However, our result is in
contrast to the literature reporting a frequency of MSI-
H in OeC between 0 and 27% in SqC [43e46] and
0e20% in AdC [22,38,43,44,47,48]. Discrepancies in the
Table 4
Comparison of mismatch repair and EBV status with clinicopathological variables in patients with gastric cancer.
Clinicopathological variables Mismatch repair proficient Mismatch repair deficient p value EBV negative EBV positive p value
LTHT KCCH Total LTHT KCCH Total LTHT KCCH Total LTHT KCCH Total
n % n % n % n % n % n % n % n % n % n % n % n %
Gender Male 415 59 250 63 665 61 42 6 33 8 75 7 0.761 456 59 273 67 729 62 26 3 22 5 48 4 0.001
Female 214 30 102 26 316 29 28 4 10 3 38 3 281 37 110 27 391 33 4 1 4 1 8 1
Unknown 3 0 1 0 4 0 1 0 1 0 2 0
(y)pT(7) T1 83 12 34 9 117 11 5 1 3 1 8 1 0.074 105 14 37 9 142 12 4 1 2 0 6 1 0.794
T2 69 10 52 13 121 11 2 0 5 1 7 1 75 10 58 14 133 11 5 1 4 1 9 1
T3 179 25 52 13 231 21 26 4 3 1 29 3 210 27 52 13 262 22 9 1 3 1 12 1
T4 301 43 214 54 515 47 37 5 32 8 69 6 348 45 236 58 584 50 12 2 17 4 29 2
Unknown 1 0 1 0 1 0 1 0
(y)pN(7) N0 206 29 70 18 276 25 22 3 13 3 35 3 0.722 242 32 82 20 324 28 13 2 4 1 17 1 0.931
N1 123 18 80 20 203 18 19 3 6 2 25 2 155 20 83 20 238 20 6 1 5 1 11 1
N2 146 21 91 23 237 22 14 2 8 2 22 2 152 20 96 23 248 21 7 1 7 2 14 1
N3 156 22 111 28 267 24 15 2 16 4 31 3 189 25 122 30 311 26 4 1 10 2 14 1
Unknown 1 0 1 0 2 0 1 0 1 0
Lauren classification Intestinal 403 57 181 46 584 53 49 7 28 7 77 7 0.022 461 60 204 50 665 56 20 3 15 4 35 3 0.919
Diffuse 145 21 154 39 299 27 10 1 10 3 20 2 185 24 156 38 341 29 6 1 10 2 16 1
Mucinous/mixed 82 12 15 4 97 9 11 2 3 1 14 1 90 12 17 4 107 9 4 1 1 0 5 0
Unknown 2 0 3 1 5 0 2 1 2 0 7 2 9 1
Neoadjuvant treatment Yes 8 1 177 45 185 17 1 0 16 4 17 2 0.305 11 1 185 45 196 17 13 3 13 1 0.293
No 624 89 164 41 788 72 69 10 27 7 96 9 727 95 185 45 912 77 30 4 13 3 43 4
Unknown 12 3 12 1 14 3 14 1
Abbreviations: KCCH, Kanagawa Cancer Center Hospital; LTHT, Leeds Teaching Hospital Trust.
p-Values in bold are considered statistically significant.
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Table 5
Summary of EBV, mismatch repair and microsatellite instability status in oesophageal and gastric cancer.
Molecular characteristics OeC GC
Oe02 LTHT UHC LTHT KCCH
n Z 443 % n Z 223 % n Z 322 % n Z 768 % n Z 410 %
EBV Negative 383 100 223 100 322 100 738 96 384 94
Positive 0 0 0 0 0 0 30 4 26 6
MMR Proficient 373 100 217 99 319 99 632 90 353 89
Deficient 1 0 3 1 3 1 70 10 43 11
Microsatellite Stable 356 98 NI NI NI NI
Instable-Low 4 1 NI NI NI NI
Instable-High 2 1 NI NI NI NI
Abbreviations: EBV, Epstein-Barr Virus; GC, gastric cancer; KCCH, Kanagawa Cancer Center Hospital; LTHT, Leeds Teaching Hospitals NHS
Trust; MMR, mismatch repair; MSI, microsatellite instability; MSS, microsatellite stable; OeC, oesophageal cancer; UHC, University Hospital
Cologne; NI, not investigated.
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to different definitions of MSI-H [47], as well as dif-
ferences in location [44] and number of microsatellite
loci tested [46]. Recent studies in GC suggest that a
mononucleotide and dinucleotide markers different to
those included in the so-called Bethesda panel might
improve accuracy and sensitivity of MSI testing in GC
[49,50].
There are few small studies reporting a MMRdef
frequency of 3e40% in OeC mostly based on IHC of
MLH1 and MSH2 [23,38,47,48]. Some of the previous
studies scores were based on staining intensity and cell
proportions and classifying cases with weak staining
and/or low percentages of positively stained tumour cells
as MMRdef. Thus, when using our MMR scoring sys-
tem where a case is classified as MMRprof, irrespective
of the number of positive nuclei or staining intensity, the
frequency of MMRdef in our study is comparable to
previously published studies. Another potential reason
for discrepant results in the literature could be the
misclassification of AdC with a tumour bulk located in
the stomach which extends into the GOJ as OeC. In
contrast to the results from the MAGIC trial patients
[22], there was no overall survival difference between
MMRdef GC and MMRprof GC in our study. This is
likely due to differences in disease stage, histological
subtypes and age of GC patients in our study.
The frequency of MMRdef and EBV positivity in our
GC cohort is consistent with the current literature
[51e53]. As the same methodology was used to stain GC
and OeC, our GC results also indirectly support the
reliability of the low frequency of MMRdef and EBV in
OeC in the present study. Furthermore, our results are
comparable with results from a smaller study in the
MAGIC trial patients comparing the frequency of MSI
and MMRdef in GC and OeC [22].
Our study has some limitations. First, this is a
retrospective study. Second, due to limited tissue avail-
ability, we were unable to perform IHC for all four
MMR proteins in all cases, and we did not test all cases
for MSI. However, evidence in the literature from GC
found MMRdef was due to loss of MLH1 in 95.8% ofcases, and deficiency in MSH6 and PMS2 was rare [51].
Similarly, a colorectal cancer study reported a positive
predictive value and specificity of IHC for MMR pro-
teins of 99.1% and 99.6%, respectively, compared with
MSI [54]. Our own study showed that MSI status is in
99.0% of cases concordant with the MMR IHC status.
Another potential limitation is our inability to deter-
mine the proportion of junctional (GOJ) AdC versus
true oesophageal or true gastric AdC which might
potentially be clinically relevant. This is related to the
fact that detailed pre-chemotherapy endoscopic infor-
mation regarding the location was not available for
most cases. There are very few studies investigating EBV
and MMRdef in GOJ cancer with inconsistent results
most likely related to low sample sizes [22,34,55] or
differences in defining the GOJ [56].
Our OeC findings suggest that OeC carcinogenesis is
not associated with EBV infection and MMRdef/MSI
does not appear to be an important underlying mecha-
nism in OeC, neither SqC nor AdC. The use of EBV
and/or MMR/MSI status to determine OeC patient
eligibility for immunotherapy or adjuvant cytotoxic
therapy cannot be recommended, and there remains the
need to find alternative biomarkers for such therapy
approaches in this patient population. The difference in
the frequency of MMRdef and EBV infection between
OeC and GC indicate not only pathophysiological dif-
ferences in oesophageal and gastric carcinomas but
might also have important implications for patient se-
lection for future treatment and study planning. In
contrast to the current practice of recruiting patients
with GC or OeC into the same trials, trials involving
immunotherapy require most likely disease specific
different designs and selection criteria for patients with
OeC.
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